

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *N Engl J Med* 2007;357:2666-76.

Supplementary Table 1

The reasons for discontinuation of study therapy

	P+B (n=347)	P (n=326)
<i>Treatment completed per protocol*</i>	17	10
<i>Disease progression</i>	171	180
<i>Toxicity/complications</i>	81	65
<i>Death</i>	6	4
<i>Patient withdrawal/refusal</i>	25	28
<i>Alternative therapy</i>	8	6
<i>Other</i>	23	21
<i>Not specified/missing</i>	16	12

**E2100 initially limited therapy to a maximum of 18 cycles. A subsequent amendment removed this stipulation and allowed treatment until PD or unacceptable toxicity.*